Biogen Highlights Kidney Disease Data at ERA and ATC 2026
CAMBRIDGE, Mass., June 3, 2026 Biogen Inc. announced that 14 abstracts from its expanding nephrology portfolio have been accepted...
kidney disease
Advertisement
Alkem Launches India’s First Semaglutide Pre-Filled Syringe
MUMBAI, India, June 2, 2026 Alkem Laboratories has announced the launch of India’s first semaglutide single-shot pre-filled syringes, marking...
Otsuka’s VOYXACT Preserves Kidney Function in Phase 3 IgAN Trial
GLASGOW, Scotland, June 4, 2026 Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc. have announced positive...
Ascidian and Lilly Sign $1.9B Kidney Disease RNA Deal
BOSTON, Massachusetts, USA, June 3, 2026 Ascidian Therapeutics and Eli Lilly and Company have entered into a landmark global...
Roche’s Gazyva Moves Closer to Public Access in Canada for Lupus Nephritis
MISSISSAUGA, Ontario, May 22, 2026 Roche Canada announced that Canada’s Drug Agency (CDA-AMC) has issued a positive reimbursement recommendation...
Advertisements
Arch Biopartners Advances Phase II AKI Trial
TORONTO, May 22, 2026 Arch Biopartners announced that Royal Columbian Hospital (RCH) in British Columbia has dosed its first...
ArteraAI Breast Gains FDA Clearance for Cancer Risk
SAN FRANCISCO, May 6, 2026 Artera announced that the U.S. Food and Drug Administration (FDA) has granted clearance for...
GSK Signs $1B SiranBio siRNA Cardiometabolic Deal
SUZHOU, China, May 6, 2026 SiranBio announced a major global licensing agreement with GSK for its investigational siRNA therapeutic...
AstraZeneca’s Ultomiris Shows Phase 3 Breakthrough in IgAN
Cambridge, United Kingdom – April 21, 2026 AstraZeneca announced that its complement inhibitor Ultomiris® (ravulizumab) achieved statistically significant and...
Akebia Therapeutics Doses First in AKB-9090 Trial
CAMBRIDGE, Mass., April 13, 2026 Akebia Therapeutics, Inc., a biopharmaceutical company focused on kidney disease, has announced that the...
Advertisement
